Borosil Scientific Ltd Q4FY26 & FY26 Results: Sales Up 10.6% & 6.6% YoY
Borosil Scientific reported Q4FY26 consolidated sales of ₹143.2 crore (up 10.6% YoY) and PAT of ₹27.2 crore (up 216.2% YoY). FY26 consolidated sales reached ₹467.3 crore (up 6.6% YoY) with PAT at ₹34.6 crore (up 29.4% YoY). The company aims for a 12-14% revenue CAGR and improved EBITDA margins.
The announcement includes detailed financial results for the quarter and the full year, along with strategic growth plans and medium-term goals, which are highly material for investors.
The company has reported significant year-on-year growth in net sales, EBITDA, and PAT for both the quarter and the full financial year, indicating strong financial performance.
Borosil Scientific Limited has announced its audited financial results for the quarter and year ended March 31, 2026. The company presented an investor presentation detailing these results, which are available on its website.
For the fourth quarter of FY26, Borosil Scientific reported consolidated net sales of ₹143.2 crore, an increase of 10.6% compared to ₹129.5 crore in the same quarter last year. Consolidated EBITDA saw a significant rise of 87.6% to ₹32.4 crore from ₹17.3 crore in Q4FY25. Consolidated Profit After Tax (PAT) surged by 216.2% to ₹27.2 crore from ₹8.6 crore in Q4FY25.
For the full financial year FY26, consolidated net sales stood at ₹467.3 crore, a 6.6% increase from ₹438.5 crore in FY25. Consolidated EBITDA grew by 16.4% to ₹64.7 crore from ₹55.6 crore in FY25, and consolidated PAT increased by 29.4% to ₹34.6 crore from ₹26.7 crore in FY25.
Standalone net sales for Q4FY26 were ₹131.9 crore, up 12.1% from ₹117.7 crore in Q4FY25. Standalone EBITDA increased by 42.2% to ₹31.5 crore from ₹22.1 crore, and standalone PAT rose by 51.9% to ₹21.5 crore from ₹14.2 crore.
For the full year FY26, standalone net sales were ₹427.5 crore, an 8.9% increase from ₹392.5 crore in FY25. Standalone EBITDA grew by 19.6% to ₹73.2 crore from ₹61.2 crore, and standalone PAT increased by 13.4% to ₹39.7 crore from ₹35.0 crore.
The company's scientific segment showed robust growth, with Lab Consumables sales up 13.4% YoY to ₹80.0 crore and Lab Equipment sales up 13.6% YoY to ₹17.1 crore in Q4FY26. The glassware segment saw a 3.9% increase in Pharma Packaging sales to ₹18.0 crore and a 7.0% increase in Domestic Glassware sales to ₹13.7 crore in Q4FY26.
Borosil Scientific highlighted its strategic focus on leveraging brand equity, new product development, export growth, and capitalizing on the 'Make in India' initiative. Medium-term goals include achieving a revenue CAGR of 12-14% and improving EBITDA margins.
What to do with a filing like this
Borosil Scientific Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Borosil Scientific Limited. Read the original for the full detail.